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Abstract
Background: Taxane-platinum therapy (TP) has replaced platinum-based therapy (PC or PAC,
DNA damaging chemotherapy) in the postoperative treatment of ovarian cancer patients;
however, it is not always effective. TP53 protein plays a differential role in response to DNA-
damaging agents and taxanes. We sought to define profiles of patients who benefit the most from
TP and also of those who can be treated with PC.
Methods: We compared the effectiveness of PC/PAC (n = 253) and TP (n = 199) with respect to
tumor TP53 accumulation in ovarian cancer patients with FIGO stage IIB-IV disease; this was a non-
randomized retrospective study. Immunohistochemical analysis was performed on 452 archival
tumors; univariate and multivariate analysis by the Cox's and logistic regression models was
performed in all patients and in subgroups with [TP53(+)] and without TP53 accumulation [TP53(-
)].
Results: The advantage of taxane-platinum therapy over platinum-based therapy was seen in the
TP53(+), and not in the TP53(-) group. In the TP53(+) group taxane-platinum therapy enhanced
the probability of complete remission (p = .018), platinum sensitivity (p = .014), platinum highly
sensitive response (p = .038) and longer survival (OS, p = .008). Poor tumor differentiation
diminished the advantage from taxane-platinum therapy in the TP53(+) group. In the TP53(-) group
PC/PAC was at least equally efficient as taxane-platinum therapy and it enhanced the chance of
platinum highly sensitive response (p = .010). However, in the TP53(-) group taxane-platinum
therapy possibly diminished the risk of death in patients over 53 yrs (p = .077). Among factors that
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positively interacted with taxane-platinum therapy in some analyses were endometrioid and clear
cell type, FIGO III stage, bulky residual tumor, more advanced age of patient and moderate tumor
differentiation.
Conclusion: Our results suggest that taxane-platinum therapy is particularly justified in patients
with TP53(+) tumors or older than 53 years. In the group of patients ≤53 yrs and with TP53(-)
tumors platinum-based therapy is possibly equally efficient. We provide hints for planning
randomized trials to verify these observations.
Background
First-line chemotherapy based on taxanes and platinum
derivatives is a standard of care for ovarian cancer patients
(taxane-platinum chemotherapy, TP) [1]; it replaced plat-
inum-cyclophosphamide (PC) or other protocols of DNA
damaging chemotherapy (PAC: platinum-doxorubicin-
cyclophosphamide, or monotherapy), further called plat-
inum-based therapy. However, taxane-platinum therapy
is more costly, neurotoxic, and 20 to 30% of patients do
not respond to this regimen [2,3]. These patients await
alternative methods of treatment. The alternative might
be a return to platinum-based therapy (PC or PAC) in
some groups of patients. Defining clinicopathological
and molecular profiles of tumors which show differential
or equal response to these two basic modes of chemother-
apy would allow for a customized treatment of ovarian
cancer patients.
The agents used in platinum-based regimens exert a cyto-
toxic effect by damaging DNA [4,5]. This eventually leads
to DNA strand-breaks and apoptosis. Apoptosis induced
by DNA damage is dependent on tumor suppressor pro-
tein TP53 [6,7]. Taxanes exert a cytotoxic effect mainly by
stabilising and inactivating microtubules responsible for
the formation of mitotic spindle [8,9]. By continuous
administration of taxol the cells are arrested in G2/M
phases, mitosis cannot be completed and this activates
apoptosis [8-11]. Apoptosis induced by taxanes is TP53
independent [12,13]. Thus, cisplatin and taxanes cause
damage to other cell structures and activate different bio-
chemical pathways.
Regarding the cisplatin treatment, impaired TP53 protein
function (usually due to TP53 gene mutation) frequently
contributes to resistance to this drug in cell line studies;
there are also some experiments showing evidence for
sensitisation or no effect of altered TP53 status on the cell
outcome [14]. Among clinical studies on ovarian cancer
patients, only a few addressed the issue of TP53 deficiency
and tumor response to platinum-based chemotherapy
[15-20]. Among these only Ferrandina et al. [17] showed
a worse response in TP53-positive tumors in a multivari-
ate analysis.
On the other hand, TP53 dysfunction may enhance tumor
sensitivity to taxanes. Although not unanimously, it has
been shown in experimental and pilot clinical studies that
ovarian carcinomas with TP53 gene mutations show a bet-
ter response to paclitaxel or paclitaxel containing regi-
mens than tumors with normal TP53 [6,12,13,21-26];
however, these results have been obtained in univariate
analyses only. To our knowledge, the role of TP53 dys-
function in taxane-platinum treated ovarian cancer
patients has not yet been evaluated in a multivariate anal-
ysis; neither were the platinum-based and taxane-plati-
num regimens compared with each other with respect to
the TP53 status. The findings presented above appear to
provide a circumstantial evidence that taxane-platinum
therapy is more efficient than platinum-based therapy in
the group with TP53 dysfunction; however, little is known
of the efficiency of the two types of regimens in the group
without evidence of TP53 dysfunction.
Immunohistochemical detection of TP53 protein accu-
mulation in tumor tissue is an inexpensive, fast and easy
method of tumor screening for the TP53 gene missense
mutation [27,28]; it is widely used in clinical studies for
evaluation of TP53 status. Although tumors with non-
sense and frameshift errors (which do not result in TP53
protein accumulation) cannot be detected by this
method, the criterion of TP53 accumulation sequestrates
tumors with the majority and with the most biologically
potent gene alterations [29,30]. In our studies TP53 pro-
tein accumulation determined the clinical significance of
other molecular factors [20,31,32].
We aimed to compare the efficiency of platinum-based
and taxane-platinum chemotherapy in subgroups uni-
form as to TP53 status in a large group of ovarian cancer
patients with advanced disease. TP53 status was deter-
mined by the lack or presence of TP53 accumulation in
tumor tissue. According to our results TP53 protein accu-
mulation is the main factor determining advantage of tax-
ane-platinum over platinum-cyclophosphamide therapy.
We are also reporting profiles of patients in whom plati-
num-cyclophosphamide therapy seems at least equally
efficient.BMC Cancer 2008, 8:27 http://www.biomedcentral.com/1471-2407/8/27
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Methods
Patients and tumors
The study was approved by the local ethics committee
(decision ref. 49/2003). We studied archival material
from 452 patients treated either with DNA damaging
chemotherapy (PC: cisplatin-cyclophosphamide or carbo-
platin-cyclophosphamide, n = 193; PAC: PC with addi-
tion of doxorubicin, n = 60, as previously described) [20]
or with standard taxane-platinum regimens (TP: paclitaxel
or docetaxel [17 patients] with cisplatin or carboplatin, n
= 199). In our previous analysis on PC and PAC treated
patients we did not observe any difference in tumor
response to these regimens [20], therefore both groups
were naturally analyzed together.
The majority of patients from the PC/PAC group were
operated on between the years 1990–1999, while from
the TP group – between the years 2000–2005. Using the
same criteria for the both chemotherapy groups optimal
cytoreduction was more frequent in the TP group (41.8%)
than in the PC/PAC group (25.3%), while suboptimal
cytoreduction showed reverse proportions (33.2% versus
54.5%, respectively). The percentage of exploratory
laparotomies was similar in the TP and PC/PAC group
(23.1% and 20.2%, respectively); the number of patients
who underwent intestinal surgery was higher in the TP
group (9% versus 5.5% in the PC/PAC group).
The median age of patients was 53 years. In the younger
patients group (≤53 yrs) optimal cytoreduction was per-
formed more frequently than in the older patients group
(>53 yrs) (36.2% versus 30.7%); a reverse proportion was
observed for the exploratory laparotomy (17.6% in
younger, 25.3% in older patients, chi-square p = 0.044).
Suboptimal cytoreduction was performed in a similar per-
centage of younger and older patients (46.2% and
44.0%); intestinal surgery was more frequent in older
patients (9.3% versus 5.3% in the younger group).
First-line chemotherapy consisted typically of 6–8 cycles
in the PC/PAC group (mean 7) and 6 cycles in the TP
group (mean 6). The number of cycles was lower if a
patient experienced progression during the first line. In
the PC/PAC treated group 90.5% of the patients com-
pleted 6 cycles of treatment; in the TP group the respective
value was 95.9%.
Only patients treated with standard protocols of chemo-
therapy were accepted for the study. For the PC regimen it
was 75 mg of cisplatin/m2 or carboplatin (350 mg/m2 or
AUC6) and 750 mg of cyclophosphamide/m2, for PAC it
was 50 mg of cisplatin/m2, 50 mg of doxorubicin/m2 and
500 mg of cyclophosphamide/m2. Taxol, given in an 24-
hour (135 mg/m2) or 3-hour infusion (175 mg/m2), or
docetaxel (75 mg/m2) was followed by cisplatin (75 mg/
m2) or carboplatin (AUC6).
For the PC/PAC group follow-up time ranged from 1.44
(two patients who experienced progression died before
completion of the first-line chemotherapy) to 195
months (median 27); the respective values for the TP
group were: 4.7–88.7 months (median 29.4). The short
follow-up resulted from early patient's death. All surviving
patients had at least a 6-month follow-up and all but six
surviving patients had at least a 2-year follow-up after the
completion of chemotherapy. Table 1 gives detailed mate-
rial characteristics.
Selection of patients and reasons for exclusion
Medical records were reviewed centrally and all tumors
were uniformly reviewed histopathologically according to
the World Health Organization criteria [33] (Table 1). The
material was carefully selected out of 899 cases submitted
to meet several criteria, among them an adequate staging
procedure that included bilateral salpingo-oophorec-
tomy, total hysterectomy, omentectomy, aspiration of
ascites or multiple cytologic washings, peritoneal biopsies
including the diaphragm, complete abdominal explora-
tion and pelvic and paraaortic node sampling (paraaortic
lymphadenectomy has been performed in some our cent-
ers as a standard since the year 2000). If necessary the pri-
mary surgery was extended to bowel surgery and tumor
debulking in the upper abdomen. However, not all cent-
ers performed such aggressive surgery. In patients who
were not operated radically (suboptimal surgery or
exploratory laparotomy) adequate staging procedure
included at least the removal of adnexal masses, omentec-
tomy or partial omentectomy or omentum biopsies,
inspection and palpation of the peritoneal cavity, retro-
peritoneum and the whole abdomen, peritoneal biopsies,
aspiration of ascites or multiple cytologic washings and
subdiaphragmatic smears.
Among other criteria of inclusion were: no chemotherapy
before staging laparotomy, International Federation of
Gynecologists and Obstetricians stage IIB to IV disease
[34], completed first-line chemotherapy (PC or PAC or
TP, as above) and tumor tissue from the first laparotomy
available.
Among the most common reasons of exclusion were: neo-
adjuvant chemotherapy, other chemotherapeutic regi-
mens, early stage disease, inadequate staging procedure,
lack of important data (residual tumor size, CA125 esti-
mations), patient drop-out, inadequate histopathological
diagnosis (a borderline tumor, a metastasis), interval
debulking or secondary cytoreduction after completion of
chemotherapy. Only a small percentage of patients under-
went second-look procedure. Patients with a microscopicBMC Cancer 2008, 8:27 http://www.biomedcentral.com/1471-2407/8/27
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Table 1: Patient characteristics (detailed data on patients in subgroups related to TP53 status and the chemotherapy type, as well as 
the number of patients at risk of recurrence and death in each subgroup at different follow-up points).
All patients, N = 452 TP53(-) group, N = 186 TP53(+) group, N = 266
Chemotherapy PC/PAC TP PC/PAC TP PC/PAC TP
N = 253 N = 199 N = 104 N = 82 N = 149 N = 117
Age
Range 24–77 20–78 24–76 20–74 25–77 33–78
mean (st.dev.) 53.9 (10.6) 54.6 (11.2) 53 (11.3) 55 (11.8) 54.5 (10.1) 54.4 (10.8)
FIGO stage
IIB, IIC 18 (7%) 10 (5%) 6 (6%) 6 (7%) 12 (8%) 4 (3%)
IIIA, IIIB 56 (22%) 28 (14%) 23 (22%) 10 (12%) 33 (22%) 18 (15%)
IIIC 145 (57%) 141 (71%) 60 (58%) 61 (74%) 86 (58%) 80 (68%)
IV 33 (13%) 20 (10%) 15 (14%) 5 (6%) 18 (12%) 15 (13%)
Residual Tumor Size
0 53 (21%) 37 (19%) 18 (17%) 16 (20%) 35 (23%) 21 (18%)
>0 ≤ 2 cm 65 (26%) 81 (41%) 30 (29%) 35 (43%) 35 (23%) 46 (39%)
>2 cm 135 (53%) 81 (41%) 56 (54%) 31 (38%) 79 (53%) 50 (43%)
Histological Type
Serous 199 (79%) 147 (74%) 72 (69%) 58 (71%) 127 (85%) 89 (76%)
Endometrioid, Clear cell 26 (10%) 13 (7%) 21 (20%) 8 (10%) 5 (3%) 5 (4%)
Undifferentiated 14 (5%) 21 (10%) 5 (5%) 7 (9%) 9 (6%) 14 (12%)
Other 14 (5%) 18 (9%) 6 (6%) 9 (11%) 8 (5%) 9 (8%)
Tumor grade
G2 31 (12%) 26 (13%) 20 (19%) 15 (18%) 11 (7%) 11 (9%)
G3 158 (62%) 115 (58%) 59 (57%) 44 (54%) 99 (66%) 71 (61%)
G4 64 (25%) 58 (29%) 25 (24%) 23 (28%) 39 (26%) 35 (30%)
TP53 accumulation
Negative 104 (41%) 82 (41%) 100% 100% 0 0
Positive 149 (59%) 117 (59%) 0 0 100% 100%
Response to chemotherapy
complete remission 135 (53%) 131 (66%) 53 (51%) 51 (62%) 82 (55%) 80 (68%)
partial remission/no change1 52 (21%) 62 (32%) 18 (17%) 31 (39%) 34 (23%) 31 (27%)
progression 66 (26%) 6 (3%) 33 (32%) 0 33 (22%) 6 (5%)
Platinum sensitive 109 (43%) 112 (56%) 46 (44%) 42 (51%) 63 (42%) 70 (60%)
Platinum highly sensitive 43 (17%) 39 (20%) 18 (17%) 12 (15%) 25 (17%) 27 (23%)
Platinum resistant 144 (57%) 87 (44%) 58 (56%) 40 (49%) 86 (58%) 47 (40%)
Follow up time for alive patients N = 30 N = 85 N = 11 N = 36 N = 19 N = 49
Range (months) 10–195 12.7–88.5 10–195 12.7–88.5 33–173.3 12.8–85.1
median 75.5 36.8 81.1 39.4 74.2 33.4
Number of patients at risk (OS)2
1 year 212 (84%) 187 (94%) 82 (80%) 78 (95%) 130 (87%) 109 (93%)
2 years 137 (54%) 132 (74%) 54 (53%) 58 (75%) 83 (56%) 75 (74%)
3 years 90 (36%) 70 (51%) 38 (38%) 26 (47%) 52 (35%) 44 (53%)
4 years 61 (26%) 45 (39%) 23 (24%) 18 (39%) 38 (27%) 27 (39%)
5 years 44 (21%) 28 (31%) 17 (19%) 12 (34%) 27 (22%) 16 (29%)
Follow up for disease-free patients3 N = 23 N = 29 N = 10 N = 10 N = 13 N = 19
Range (months) 8.7–187.3 14.6–80.6 15.2–187.3 14.6–69.3 8.7–164.7 14.8–80.6
median 76.2 38.1 68.6 33.6 82.8 38.2
Number of patients at risk (DFS)2
1 year 72 (54%) 75 (56%) 33 (62%) 27 (53%) 39 (49%) 48 (59%)
2 years 43 (33%) 39 (33%) 18 (35%) 12 (27%) 25 (31%) 27 (38%)
3 years 34 (26%) 23 (26%) 14 (27%) 7 (21%) 20 (25%) 16 (28%)
4 years 24 (20%) 14 (21%) 11 (23%) 5 (21%) 13 (18%) 9 (21%)
5 years 17 (17%) 6 (14%) 8 (21%) 2 (11%) 9 (15%) 4 (21%)
PC – cyclophosphamide and cisplatin, PAC – PC plus doxorubicin, TP-taxane-platinum therapy; 1we have combined these responses because it was 
not always possible to have objective measures of the disease in the restrospective study; OS-overall survival, DFS – disease free survival; 2based on 
Kaplan-Meier estimator, 3 those who had complete remission onlyBMC Cancer 2008, 8:27 http://www.biomedcentral.com/1471-2407/8/27
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recurrence were excluded, because they received a second-
line chemotherapy and could not be compared with
patients who were observed only clinically and biochem-
ically. Patients with well differentiated tumors were
excluded, because apparently chemotherapy is of no ben-
efit in low grade disease [35].
Evaluation of clinical response to chemotherapy
Response to chemotherapy was evaluated retrospectively
according to the World Health Organization response
evaluation criteria [36]. The evaluation was based on data
from medical records describing patient's clinical condi-
tion and CA125 levels in 3–4 week intervals. Complete
remision (CR) was defined as disappearance of all clinical
and biochemical symptoms of ovarian cancer evaluated
after completion of first-line chemotherapy and con-
firmed at four weeks. Within the complete remission (CR)
group we have identified platinum sensitive groups (PS,
disease free survival longer than six months) and plati-
num highly sensitive groups (PHS, disease free survival
longer than 24 months). Other tumors were described as
platinum resistant [37] (Table 1).
Immunohistochemical analysis
Immunohistochemical stainings were performed on par-
affin-embedded material after heat-induced epitope
retrieval (HIER). We used PAb1801 monoclonal antibody
(1:3000, Sigma-Genosys, Cambridge, UK) for TP53 pro-
tein. This antibody detects both wild type and mutant
TP53 proteins. In our experience it is highly effective in
detecting tumors with TP53 gene missense mutations
[27,28].
Deparaffinized sections were boiled in a citrate buffer (pH
6,0) at 700 Watts in a microwave 2 × 5 min. Non-specific
tissue and endogenous peroxidase reactivity were blocked
with 10% BSA and 3% H2O2, respectively. Tissue sections
were incubated overnight at 4°C. Biotinylated goat anti-
mouse IgG (1: 1500, cat. no.816), peroxidase conjugated
streptavidin (1:500, cat. no. 309) (both from Immu-
notech, Marseille, France), and DAB were used as a detec-
tion system. Ovarian carcinomas with and without TP53
gene missense mutation were controls for TP53. Normal
mouse IgG of the same subclass and concentration as the
primary antibody also served as a negative control.
Semiquantitative evaluation of the immunohistochemi-
cal staining was performed by a pathologist (JK). TP53
protein accumulation was described as present (more
than 10% of positive cells, TP53-positive) or absent
(TP53-negative). According to our experience from differ-
ent studies, and with the HIER method applied in the
detection of TP53, 10% is the optimal cut-off value for
separation of tumors with and without a TP53 gene mis-
sense mutation [27,28,38].
Statistical analysis
Associations between protein expression and clinico-
pathological variables were studied by chi-square test.
Overall survival and disease free survival analyses were
performed with the Kaplan-Meier method and the multi-
variate Cox's proportional hazards models. Tumor
response to chemotherapy was evaluated in the multivar-
iate logistic regression model. Significant parameters were
selected by stepwise elimination from the model. The
analysis was performed in all carcinomas, and separately
in tumors with [TP53(+)] and without TP53 accumula-
tion [TP53(-)] [20]. In the smaller TP53(-) group (n =
186) a two-sided log rank test achieved 80% power at a
0,05 significance level to detect a difference of 15% of
patients surviving 1 year between the two chemotherapy
groups. All tests were two-sided and the level of signifi-
cance was set at 5%.
Analysis of interaction between the evaluated chemotherapies and 
other factors
We also studied the relative efficiency of the main types of
chemotherapy (TP versus PC/PAC) in various clinical and
pathological subgroups. For example, not only patients
with FIGO IIIC disease but also patients with FIGO IIIC
disease treated with PC/PAC, and patients with FIGO IIIC
disease treated with TP were compared to patients with
FIGO IIB/C disease. These analyses were performed in the
multivariate models. If the odds of achieving a given end-
point differed significantly between the both chemother-
apy groups, it meant that one chemotherapeutic regimen
was more efficient in the FIGO IIIC group (in other words
it showed an interaction with FIGO IIIC).
Counting cumulated odds/hazards of achieving a given endpoint with 
the two chemotherapy regimens
PC/PAC and TP chemotherapy showed interaction with
several clinicopathological parameters. In some patients
the interaction was contradictory. For example, TP was
more efficient in older patients, but less efficient in
patients with undifferentiated tumors. To find out how
various parameters and the two main chemotherapeutic
regimens contribute to the final clinical effect we counted
cumulated odds or hazards as in the example below.
Hazards of death in the TP53(+) group were as follows:
the PC/PAC treated group served as a reference with HR
1.0 for all factors; risk of death for TP therapy was lower
(HR 0.15) (see Table 2); for patients >53 years treated
with TP the risk of death was lower (HR 0.58); for patients
with grade 4 tumors treated with TP the risk of death was
higher (HR 6.0). Thus, the cumulated hazard of death
(with respect to these parameters only) in the TP53(+)
group for a patient treated with PC/PAC (HR 1.0), older
than 53 yrs (HR 1.0), with grade 4 tumors (HR 1.0) was
1.0 (1.0 × 1.0 × 1.0). The relative cumulated hazard ofBMC Cancer 2008, 8:27 http://www.biomedcentral.com/1471-2407/8/27
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death in the TP53(+) group for a patient treated with TP
(HR 0.15), older than 53 yrs (HR 0.58), with grade 4
tumors (HR 6.0) was 0.52 (0.15 × 0.58 × 6.0), i.e. it was
nearly two times lower than with PC/PAC. All odds or
hazards (OR, HR) were obtained in multivariate models.
Results
TP53 accumulation
Exactly the same percentage of ovarian carcinomas from
the PC/PAC and taxane-platinum group were positive for
TP53 protein accumulation (59%, Table 1). TP53 protein
accumulation was associated with tumor grade 3 and 4 (p
= 0.004) and with serous tumor type (p < 0.001); it did
not associate with clinical factors or with clinical end-
points.
Taxane-platinum versus platinum-based chemotherapy 
and clinical endpoints
Analysis of the TP53-negative group
In the TP53(-) group, complete remission (CR), platinum
sensitivity, disease-free survival and overall survival were
not influenced by the type of chemotherapy (Table 2).
Platinum highly sensitive response (PHS) was more prob-
able with PC/PAC regimen (OR 1.0 for PC/PAC, OR 0.006
for TP, Table 2). The latter was reflected mainly in patients
with FIGO IIB/C and IV disease: patients with FIGO IIB/C
had strikingly higher frequency and odds of PHS response
when treated with PC/PAC (83% PHS versus 20% in the
TP treated group), and the same was observed for FIGO IV
disease (7% PHS versus 0 in the TP treated group) (cumu-
Table 2: Taxane-platinum (TP) versus platinum-based therapy (PC/PAC) in the TP53-negative and TP53-positive group. Interactions 
between the therapies and clinicopathological factors (multivariate models: the logistic regression and Cox proportional hazards 
model)*
TP53(-) group, N = 186 TP53(+) group, N = 266
OR or HR [95% C.I.] P value OR or HR [95% C.I.] P value
Complete remission (CR)
PC/PAC - 1.0
TP - >0.1 3.28 [1.22,8.83] 0.018
endometrioid, CCC treated with PC/PAC 1.0 -
endometrioid, CCC treated with TP >10 [0.92, +] 0.058 -
Platinum sensitivity (PS)
PC/PAC - 1.0
TP - >0.1 1.96 [1.14, 3.35] 0.014
Platinum high sensitivity (PHS)
PC/PAC 1.0 1.0
TP 0.006 [0.001, 0.29] 0.010 10.73 [1.14, +] 0.038
endometrioid, CCC treated with PC/PAC 1.0 -
endometrioid, CCC treated with TP 18.37 [1.25, +] 0.033 -
FIGO IIIA/B treated with PC/PAC 1.0 -
FIGO IIIA/B treated with TP 161 [3.08, +] 0.012 -
FIGO IIIC treated with PC/PAC 1.0 -
FIGO IIIC treated with TP 133 [2.94, +] 0.012 -
Residual tumor >2 cm treated with PC/PAC - 1.0
Residual tumor >2 cm treated with TP - 5.95 [1.16, +] 0.032
Grade 3 tumors treated with PC/PAC - 1.0
Grade 3 tumors treated with TP - 0.11 [0.01, 1.14] 0.065
Grade 4 tumors treated with PC/PAC - 1.0
Grade 4 tumors treated with TP - 0.04 [0.003, 0.55] 0.016
Disease free survival (DFS)
PC/PAC versus TP >0.1 >0.1
Overall survival (OS, risk of death)
PC/PAC - 1.0
TP - >0.1 0.15 [0.04, 0.60] 0.007
Age >53 treated with PC/PAC 1.0 1.0
Age >53 treated with TP 0.51 [0.24, 1.08] 0.077 0.58 [0.32, 1.07] 0.080
Grade 3 tumors treated with PC/PAC - 1.0
Grade 3 tumors treated with TP - 5.76 [1.44, 23.0] 0.013
Grade 4 tumors treated with PC/PAC - 1.0
Grade 4 tumors treated with TP - 6.0 [1.43, 25.5] 0.015
CCC – clear cell carcinoma; *this table shows only parameters which interacted with the chemotherapies; the clinical endpoints were also 
associated with other clinicopathological factors or their categories (see Table 3)BMC Cancer 2008, 8:27 http://www.biomedcentral.com/1471-2407/8/27
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lated OR 1.0 for PC/PAC, 0.01 to 0.006 for TP depending
on histological tumor type, as below).
Analysis of the relative efficiency of the two types of chem-
otherapy revealed that patients with FIGO IIIA/B and IIIC
disease, and with endometrioid and clear cell carcinomas
would have higher chances of PHS response with taxane-
platinum than with platinum-based therapy (Table 2);
however, this effect was diminished by the generally lower
odds of PHS with taxane-platinum therapy. Also, the odds
of complete remission appeared higher after TP therapy in
the group of endometrioid and clear cell carcinomas (p =
0.058, Table 2). However, some interactions were esti-
mated on the basis of small patients groups and the odds
had large confidence intervals; to determine their cumula-
tive impact on reaching PHS or CR response in the TP53(-
) group further studies would be necessary.
Overall survival curves have shown that in the TP53(-)
group patient's age over median determined benefits from
TP therapy (log rank: p = 0.0027, fig. 1). TP therapy in the
group of patients ≤53 yrs did not seem to improve overall
survival when compared with PC/PAC therapy (log rank:
p = 0.37, fig. 2). In multivariate analysis there was a trend
only (beyond the border of significance) suggesting that
TP therapy might diminish the risk of death in patients
older than 53 years (Table 2).
All clinicopathological factors influencing clinical end-
points in the TP53-negative and TP53-positive group are
shown in Table 3.
Analysis of the TP53-positive group
Taxane-platinum therapy in the TP53(+) group enhanced
the chances of complete remission, platinum sensitivity
and platinum highly sensitive response (PHS) when com-
pared with PC/PAC therapy (Table 2). As to the odds of
PHS, the greatest difference between the therapies was
observed in patients with residual tumor above 2 cm
(Tables 2 and 4). Also, patients with moderately differen-
tiated tumors (G2) treated with taxane-platinum com-
pounds had over a 10 times higher chance of PHS
response than those treated with PC/PAC (final OR 10.7
for TP, 1 for PC/PAC, Table 4). On the other hand, tumor
undifferentiation (grade 4) diminished the odds of the
platinum highly sensitive response to TP therapy and
enhanced the same to PC/PAC therapy (Table 2). This
effect was particularly visible in patients with residual
tumor ≤2 cm (cumulated OR 0.43 for TP, 1.0 for PC/PAC;
Table 4). A similar impact of poor tumor differentiation
(grade 3) was weaker (Tables 2 and 4).
Risk of death was 6 times lower for patients treated with
taxane-platinum than for those treated with PC/PAC
(Table 2). There was a tendency for the highest advantage
from taxane-platinum in patients over 53 years (p = 0.080,
Table 2) (fig. 3) or with G2 tumors (fig. 4). Poor tumor
differentiation (G3 or G4) relatively enhanced risk of
death in patients treated with taxane-platinum com-
pounds (Table 2).
Concomitant evaluation of three parameters influencing a
given clinical endpoint (i.e. a product of odds ratios of
age, grade, residual tumor size) might suggest that in the
Kaplan-Meier curves for overall survival in the TP53(-) group  in patients at the age of 53 years (median) or younger Figure 2
Kaplan-Meier curves for overall survival in the TP53(-) group 
in patients at the age of 53 years (median) or younger.
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Table 3: All clinicopathological factors influencing clinical endpoints in the TP53-negative and TP53-positive group.
TP53(-) group, N = 186 TP53(+) group, N = 266
OR or HR [95% C.I.] P value OR or HR [95% C.I.] P value
Complete remission (CR)
PC/PAC - 1.0
TP - >0.1 3.28 [1.22,8.83] 0.018
Age ≤53 yrs 1.0 -
Age >53 0.53 [0.27,1.02] 0.057 -
Residual tumor 0 1.0 1.0
Residual tumor ≤2 cm 0.15 [0.01,0.54] 0.004 -
Residual tumor >2 cm 0.06 [0.02,0.24] 0.000 0.16 [0.094,0.29] 0.000
other histological types 1.0 -
endometrioid, CCC 0.28 [0.08, 0.96] 0.044 -
FIGO IIB-IIIC - 1.0
FIGO IV - 0.35 [0.15,0.81] 0.014
Platinum sensitivity (PS)
PC/PAC - 1.0
TP - >0.1 1.96 [1.14, 3.35] 0.014
Residual tumor 0 1.0 1.0
Residual tumor ≤2 cm 0.15 [0.054, 0.45] 0.001 -
Residual tumor >2 cm 0.08 [0.028, 0.23] 0.000 0.21 [0.126, 0.36] 0.000
FIGO IIB–IIIC - 1.0
FIGO IV - 0.38 [0.158, 0.91] 0.031
Platinum high sensitivity (PHS)
PC/PAC 1.0 1.0
TP 0.006 [0.001, 0.29] 0.010 >10 [1.14, +] 0.038
FIGO IIB/C 1.0 1.0
FIGO IIIA/B 0.06 [0.004, 0.68] 0.024 -
FIGO IIIC 0.01 [0.001, 0.18] 0.001 0.47 [0.21,1.07] 0.075
FIGO IV 0.008 [0.000, 0.20] 0.003 0.13 [0.02,0.72] 0.021
Residual tumor 0 - 1.0
Residual tumor ≤2 cm - 0.012 0.41 [0.18,0.96] 0.04
Residual tumor >2 cm - 0.09 [0.02, 0.37] 0.001
Disease free survival (DFS)
PC/PAC versus TP >0.1 >0.1
FIGO IIB-IIIB 1.0 1.0
FIGO IIIC 2.17 [1.31,3.60] -
FIGO IV 3.04 [1.22,7.62] 0.003 2.20 [1.17,4.16] 0.014
Grade 3,4 - 0.017 1.0
Grade 2 - 0.34 [0.16,0.72] 0.005
Residual tumor 0 - 1.0
Residual tumor ≤2 cm - 1.68 [1.07,2.64] 0.023
Residual tumor >2 cm - 2.14 [1.34,3.39] 0.001
Overall survival (OS)
PC/PAC - 1.0
TP - >0.1 0.15 [0.04, 0.60] 0.007
Age 53 1.0 1.0
Age >53 1.5 [0.95, 2.25] 0.085 1.66 [1.14, 2.41] 0.008
Residual tumor 0 1.0 1.0
Residual tumor ≤2 cm 2.48 [1.42,4.32] 0.001 1.72 [1.07,2.75] 0.023
Residual tumor >2 cm 3.13 [1.83,5.34] 0.000 2.43 [1.52,3.9] 0.000
other histological types 1.0 -
endometrioid, CCC 1.76 [1.09,2.85] 0.02 -
FIGO IIB/C - 1.0
FIGO IIIA/B - 2.1 [0.92,4.76] 0.078
FIGO IIIC - 2.58 [1.13,5.87] 0.024
FIGO IV - 5.04 [2.06,12.27] 0.000BMC Cancer 2008, 8:27 http://www.biomedcentral.com/1471-2407/8/27
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TP53(+) group there was a subgroup with higher chances
of platinum highly sensitive response with PC/PAC ther-
apy without compromising overall survival. This group
was characterized by younger patient's age, residual tumor
≤2 cm, tumor grade 4 (Tables 4 and 5).
Analysis of the whole group
For comparison with data from the literature we also ana-
lyzed the whole patient group. Taxane-platinum therapy
was more efficient than PC/PAC (OR 1.0) with regard to
complete remission (OR for TP 1.57, 95% C.I. [1.03,
2.39], p = 0.035), platinum sensitivity (OR for TP 1.65,
95% C.I. [1.09, 2.50], p = 0.016) and overall survival (HR
for TP 0.37, 95% C.I. [0.16, 0.81], p = 0.014); taxane-plat-
inum therapy did not influence disease free survival and
the probability of achieving platinum highly sensitive
response (PHS). The latter was probably a result of contra-
dictory associations between PHS and the therapies in the
TP53(-) and TP53(+) groups.
Analysis of interactions revealed advantages or disadvan-
tages of taxane-platinum therapy in some subgroups of
patients, in accord with the results presented above, i.e.
taxane-platinum therapy was more efficient than PC/PAC
in patients with RT > 2 cm (platinum highly sensitive
response, OR for TP 3.52, 95% C.I. [1.10, 11.27], p =
0.033), older than 53 years (overall survival, HR for TP
0.62, 95% C.I. [0.38, 0.97], p = 0.04), while it was less
advantageous in cases with high tumor grade – G3 (over-
all survival, HR for TP 2.32, 95% C.I. [1.04, 5.17], p =
0.039) and G4 (overall survival, HR for TP 2.62, 95% C.I.
[1.11, 6.18], p = 0.027).
Discussion
There are four major randomized studies comparing plat-
inum-based and taxane-platinum therapy (TP) in ovarian
cancer patients and they present inconsistent results
[1,39-41]. Nevertheless, taxane-platinum therapy has
become a gold standard in the treatment of this disease.
Its ineffectiveness in nearly a quarter of patients remains a
real problem and identification of such patients prior to
chemotherapy would allow for choosing alternative
methods of treatment.
Our analysis of the whole group studied shows the supe-
riority of TP over PC/PAC, and in this aspect it is in accord
with the results of GOG 111 and OV-10 studies. However,
Kaplan-Meier curves for overall survival in the TP53(+) group  in relation to tumor grade Figure 4
Kaplan-Meier curves for overall survival in the TP53(+) group 
in relation to tumor grade.
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Table 4: TP53-positive group. Cumulated odds of achieving 
platinum highly sensitive response with the two therapies in 
patients with various combinations of residual tumor size and 
tumor grade (the odds are based on multivariate models, table 
2).
Residual tumor 
(RT)
Tumor 
grade
Cumulated odds 
PC/PAC
Cumulated odds 
TP
0 2 1 10.73
≤2 cm 2 1 10.73
>2 cm 2 1 63.84
0 3 1 1.18
≤2 cm 3 1 1.18
>2 cm 3 1 7.02
04 10 . 4 3
≤2 cm 4 10 . 4 3
>2 cm 4 1 2.55
The odds are higher for taxane-platinum therapy in all patients with 
residual tumor >2 cm or with grade 2 tumors. The odds are higher for 
platinum-based therapy in patients with grade 4 tumors and residual 
tumor 0–≤2 cm (bold). For other patients the odds for the two 
chemotheraputic regimens are similar.
Kaplan-Meier curves for overall survival in the TP53(+) group  in relation to patients' age Figure 3
Kaplan-Meier curves for overall survival in the TP53(+) group 
in relation to patients' age.BMC Cancer 2008, 8:27 http://www.biomedcentral.com/1471-2407/8/27
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we have possibly identified profiles of ovarian cancer
patients who benefit most from first-line taxane-platinum
therapy (TP), and also of those in whom platinum-based
therapy (PC or PAC) appears at least equally efficient.
In our non-randomized retrospective study TP53 protein
accumulation in tumor tissue was the main criterion of
higher benefits from TP than from PC/PAC chemother-
apy; in the TP53-negative group taxane-platinum therapy
did not show any clear advantages over platinum-cyclo-
phosphamide therapy. A similar observation was pub-
lished by Zhao et al [42] who retrospectively analyzed 53
patients treated either with taxane-platinum or platinum-
cyclophosphamide. Although their subgroups of patients
were small they observed significantly higher rates of
complete remissions with taxane-platinum therapy in the
TP53(+) group only [42].
The observed advantage of taxane-platinum therapy in the
group with TP53 accumulation is in accord with some ear-
lier data from experimental and pilot clinical studies [21-
23]. The clinical studies evaluating 38–48 patients treated
with taxane-platinum compounds demonstrated better
tumor response in the group with TP53 dysfunction
[21,22]. Similar results were recently published by Ueno
et al on larger group of 100 patients [24]. At a molecular
level better sensitivity to paclitaxel in TP53 dysfunctional
cells is not completely understood; a bypass of G1 check-
point, an increase in G2/M arrest or loss of the TP53-
dependent post-mitotic spindle checkpoint have been
proposed as explanations [12,23].
In our study the patient's age over median (53 years in our
material) appears as another important criterion of
advantage of TP over PC/PAC therapy. This factor did not
reach statistical significance in multivariate analysis, nev-
ertheless, patients older than 53 years treated with PC/
PAC had the worst survival rate. This result means a worse
survival for older than for younger patients treated with
PC/PAC, as it was shown in our previous multivariate
analyses on the PC/PAC group only [20,31]; TP treated
patients seem to have a similar survival rate in the both
age groups [[43], Ziolkowska-Seta et al: TP53, BCL-2 and
BAX expressions as predictors of ovarian cancer response
to taxane-platinum therapy, submitted]. Possible mecha-
nisms of the inferior results of cisplatin/cyclophospha-
mide treatment in the elderly may be due to slower
metabolism of cyclophosphamide to active metabolites,
higher cisplatin area under curve (AUC), higher toxicity
and related morbidity; however, clinical analyses on age-
related pharmacokinetics of these drugs are fragmentary
and do not always confirm preclinical findings [44,45].
Of secondary importance in the criteria of benefits from
taxane-platinum therapy observed in our study (in the
TP53-positive group only) were bulky residual tumor and
moderate tumor differentiation. This partially confirms
the results of previous clinical studies showing that TP
therapy improves survival in suboptimally debulked
patients [1,40,46]. As TP therapy was generally much
more efficient than PC/PAC in the TP53(+) group, its
higher efficiency may be more visible in large tumor mass
than in small or no tumor mass.
Spectacularly high efficacy of TP in moderately differenti-
ated tumors and much lower in undifferentiated tumors
(and concomitantly the opposite for platinum-based ther-
apy) has not been reported previously. Poor tumor differ-
entiation/undifferentiation appears as a factor
significantly leveling the benefits from TP therapy in the
TP53-positive group. While better effects of platinum-
based therapy in undifferentiated tumors might be
explained by loss of DNA repair in undifferentiated cells,
we could not find a clear explanation for the observed
associations between tumor grade and TP therapy. The
mechanisms underlying taxol resistance include muta-
tions in the β-tubulin gene [47-49], differential expression
of  β-tubulin isotypes [50,51], and altered microtubule
dynamics [52]. The alterations may be more pronounced
in less differentiated tumors. Several studies on cell lines
demonstrated differences in the expression of beta-tubu-
lin subtypes depending on cell differentiation; a higher
stability of microtubules and lower activity of taxanes in
differentiated cells was also described [53,54]. Shakuto et
al observed better tumor suppression in vivo by paclitaxel
in well differentiated than in moderately differentiated
tumors [55].
We also observed that patients with endometriod and
clear cell carcinomas treated with TP showed a better
response than those treated with PC/PAC (in the TP53-
negative group only). This may be due to the high expres-
sion of apoptosis inhibitor BCL-2 in these histological
Table 5: TP53-positive group. Cumulated hazards of death in 
patients with various combinations of age and tumor grade (the 
hazards are based on multivariate models).
Age Tumor grade Cumulated hazards 
PC/PAC
Cumulated hazards 
TP
≤53 2 1 0.15
≤53 3 1 0.86
≤53 4 1 0.90
>53 2 1 0.08
>53 3 1 0.50
>53 4 1 0.52
The hazards of death are strikingly lower for taxane-platinum therapy 
in patients older than 53 years or with grade 2 tumors. For other 
patients the hazards for the two chemotheraputic regimens are close.BMC Cancer 2008, 8:27 http://www.biomedcentral.com/1471-2407/8/27
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types and its inactivation by taxanes [20,56]. However,
this association was not strong enough to show an effect
on overall survival in patients younger than 53 years. An
analysis of a larger group of endometriod and clear cell
carcinomas should be performed with respect to the two
types of therapy.
A striking observation was the much lower rate of
responses to taxane-platinum therapy in FIGO II and IV
disease in the TP53-negative group. These may be candi-
date groups for platinum-based therapy of choice. Due to
the small number of cases further clinical studies focused
on these subgroups including also FIGO IC-IIA disease
may provide greater insight.
The results of our analysis are presented and discussed
with the limitation that this is a non-randomized retro-
spective study. Therefore, there is some bias in our analy-
sis related to differences in the material characteristics
between the therapies. Nevertheless, the main focus of our
study was the analysis across TP53 status and the results
have been obtained in a multivariate analysis. Our study
suggests the superiority of taxane-platinum therapy in the
majority of patients with TP53(+) tumors and in any one
older than 53 years. It also questions the necessity of tax-
ane-platinum therapy in some subgroups of younger
ovarian cancer patients. We provide hints for planning
randomized trials to verify these observations.
Conclusion
According to our non-randomized study, TP53 protein
accumulation appears as the main factor determining
benefits from taxane-platinum therapy in ovarian cancer
patients. Another factor may be the more advanced age of
the patient. Thus, our study confirms the advantage of tax-
ane-platinum therapy in the majority of patients. Never-
theless, the prospect does exist for a return to platinum-
cyclophosphamide therapy in some subgroups of
patients, predominantly of those younger than 53 yrs with
TP53-negative tumors. Our results give hints for rand-
omized trials.
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